AMPH

Peers: AMRX ANIP XERS RDY TEVA EBS VTRS ALVO BAX SPRY

| Held by: IJR AVUV DFSV VTI IWM DFAT VXF DFAS IWN SPSM

Index	RUT
Market Cap	1.11B
Enterprise Value	1.50B
Income	78.55M
Sales	730.02M
Book/sh	18.06
Cash/sh	6.88
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	1976
IPO	Jun 25, 2014

P/E	15.26
Forward P/E	8.21
PEG	7.14
P/S	1.52
P/B	1.44
P/C	3.79
P/FCF	7.25
EV/EBITDA	8.40
EV/Sales	2.06
Quick Ratio	1.71
Current Ratio	2.40
Debt/Eq	0.90
LT Debt/Eq	0.88
Option/Short	Yes / Yes

EPS (ttm)	1.71
EPS next Y	3.17
EPS next Q	0.86
EPS this Y	-8.88%
EPS next Y	7.09%
EPS next 5Y	1.15%
EPS past 3/5Y	5.29% 134.65%
Sales past 3/5Y	12.99% 15.53%
EPS Y/Y TTM	-38.09%
Sales Y/Y TTM	1.02%
EPS Q/Q	6.44%
Sales Q/Q	5.44%
Earnings	Aug 06 AMC
EPS/Sales Surpr.	46.75% 2.21%

Insider Own	27.35%
Insider Trans	-0.29%
Inst Own	68.00%
Inst Trans	-9.58%
ROA	4.68%
ROE	10.30%
ROIC	5.44%
Gross Margin	45.61%
Oper. Margin	15.66%
Profit Margin	10.76%
SMA20	-0.12%
SMA50	7.28%
SMA200	16.78%
Trades

Shs Outstand	42.53M
Shs Float	30.91M
Short Float	14.25%
Short Ratio	9.49
Short Interest	4.41M
52W High	29.52 -11.79%
52W Low	16.65 56.44%
Volatility	3.11% 3.63%
ATR (14)	0.79
RSI (14)	56.23
Beta	0.94
Rel Volume	0.00
Avg Volume	464.18K
Volume	10

Perf Week	0.66%
Perf Month	-0.88%
Perf Quarter	35.77%
Perf Half Y	21.63%
Perf YTD	-2.76%
Perf Year	5.34%
Perf 3Y	-41.77%
Perf 5Y	35.70%
Perf 10Y	40.08%
Recom	3.14
Target Price	22.50
Prev Close	26.04
Price	26.04
Change %	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-29-26	Downgrade	BofA Securities	Neutral → Underperform	$20
May-14-26	Downgrade	Wells Fargo	Overweight → Equal Weight	$19
May-08-26	Downgrade	Needham	Buy → Hold
Apr-21-26	Downgrade	Jefferies	Buy → Hold	$22
Dec-09-25	Initiated	Barclays	Equal Weight	$30
Aug-12-25	Upgrade	Needham	Hold → Buy	$36
May-12-25	Downgrade	JP Morgan	Overweight → Neutral	$30
Feb-04-25	Downgrade	Piper Sandler	Overweight → Neutral	$66 → $36
Nov-22-24	Initiated	Wells Fargo	Equal Weight	$55
Mar-05-24	Initiated	JP Morgan	Overweight	$60
Nov-17-23	Initiated	BofA Securities	Neutral	$63
Jul-25-23	Resumed	Jefferies	Buy	$70
Oct-21-22	Resumed	Jefferies	Buy	$36
Jul-29-22	Initiated	CapitalOne	Overweight	$44
Jan-07-22	Upgrade	Piper Sandler	Neutral → Overweight	$21 → $28
Jan-08-21	Downgrade	Wells Fargo	Overweight → Equal Weight	$21
Oct-05-20	Upgrade	Northland Capital	Market Perform → Outperform	$24
May-01-20	Initiated	Northland Capital	Outperform	$23
Mar-13-19	Downgrade	Piper Jaffray	Overweight → Neutral	$24 → $23
Mar-13-19	Downgrade	Needham	Buy → Hold

Show Previous Ratings

Sep-01-26 06:00AM	Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference (PR Newswire)
Aug-06-26 05:04PM	Amphastar: Q2 Earnings Snapshot (Associated Press)
04:05PM	Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 (PR Newswire)
Jul-29-26 06:00AM	Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 6, 2026 (PR Newswire)
Jun-29-26 12:01PM	BofA cuts ratings on four biopharma stocks over valuation and catalyst concerns (Investing.com)
06:00AM	Loading…
May-27-26 06:00AM	Amphastar Pharmaceuticals to Present at the 2026 Jefferies Healthcare Conference (ACCESSWIRE)
May-07-26 04:41PM	Amphastar: Q1 Earnings Snapshot (Associated Press) -20.93%
04:05PM	Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 (ACCESSWIRE)
May-06-26 06:00AM	Amphastar Pharmaceuticals to Present at the 2026 Bank of America Health Care Conference (ACCESSWIRE)
Apr-30-26 06:00AM	Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7, 2026 (ACCESSWIRE)
Apr-06-26 06:00AM	Amphastar Pharmaceuticals to Present at the 25th Annual Needham Healthcare Conference (ACCESSWIRE)
Mar-04-26 10:31PM	Generic Pharmaceuticals Stocks Q4 Highlights: Amphastar Pharmaceuticals (NASDAQ:AMPH) (StockStory)
06:00AM	Amphastar Pharmaceuticals to Present at the Barclays 28th Annual Global Healthcare Conference (ACCESSWIRE)
Mar-02-26 10:23AM	Wells Fargo Sees Amphastar Pharmaceuticals, Inc.'s (AMPH) AMP-007 as Key to Mid- to High-Single-Digit Growth (Insider Monkey)
Feb-27-26 12:36PM	Why Amphastar Pharmaceuticals (AMPH) Shares Are Plunging Today (StockStory) -23.63%
12:03AM	Loading…
12:03AM	Amphastar Pharmaceuticals Inc (AMPH) Q4 2025 Earnings Call Highlights: Resilient Growth Amidst ... (GuruFocus.com)
Feb-26-26 10:07PM	Amphastar Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat) -5.29%
08:30PM	Compared to Estimates, Amphastar (AMPH) Q4 Earnings: A Look at Key Metrics (Zacks)
05:30PM	Amphastar Pharmaceuticals (AMPH) Q4 Earnings and Revenues Lag Estimates (Zacks)
05:27PM	Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q4 CY2025 Revenue Estimates, Stock Drops 11.7% (StockStory)
04:32PM	Amphastar: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full Year Ended December 31, 2025 (ACCESSWIRE)
Feb-25-26 09:59AM	Amphastar Pharmaceuticals (AMPH) Reports Earnings Tomorrow: What To Expect (StockStory)
Feb-24-26 06:00AM	Amphastar Announces FDA Approval for Ipratropium Bromide HFA (ACCESSWIRE)
Feb-23-26 10:45AM	Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings? (Zacks)
Feb-20-26 06:00AM	Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 26, 2026 (ACCESSWIRE)
Feb-17-26 10:30AM	CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock? (Zacks)
Feb-13-26 03:50PM	Amphastar Pharmaceuticals, Novavax, and Organon Shares Skyrocket, What You Need To Know (StockStory)
Feb-12-26 09:17AM	Do Options Traders Know Something About Amphastar Pharmaceuticals Stock We Don't? (Zacks)
Feb-11-26 08:01AM	CorMedix Banks on DefenCath Sales in Q4 as Melinta Adds Upside (Zacks)
08:39AM	Loading…
Jan-30-26 08:39AM	CRMD Down 31% in a Month: Is This an Indication to Sell the Stock? (Zacks)
Jan-23-26 10:59AM	Will CRMD'S Bearish 2026 View Impact DefenCath's Long-Term Adoption? (Zacks)
Jan-15-26 03:46PM	Why Amphastar Pharmaceuticals (AMPH) Stock Is Nosediving (StockStory) -6.34%
08:38AM	Will DefenCath Continue to Aid CorMedix's Top Line in Q4 Earnings? (Zacks)
Jan-14-26 11:04PM	2 Reasons to Avoid AMPH and 1 Stock to Buy Instead (StockStory)
06:23PM	Amphastar Pharmaceuticals Touts Shift to Proprietary Drugs, Teases AMP-007 Launch and Baqsimi Growth (MarketBeat)
Jan-12-26 04:05PM	Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today (StockStory) +5.98%
06:00AM	Amphastar Pharmaceuticals Announces Exclusive License Agreement with Nanjing Hanxin Pharmaceutical Technology Co., Ltd. for Fully Synthetic Corticotropin Compound (ACCESSWIRE)
Jan-07-26 06:00AM	Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference (ACCESSWIRE)
Dec-26-25 09:12AM	Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath? (Zacks)
Dec-15-25 06:00AM	Amphastar Announces FDA Approval for Teriparatide Injection (ACCESSWIRE)
Dec-11-25 10:57AM	CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock? (Zacks)
Dec-05-25 09:23AM	Can DefenCath Continue to Aid CorMedix's Long-Term Growth Ahead? (Zacks)
Dec-03-25 03:26PM	Amphastar Pharmaceuticals (AMPH) Stock Trades Up, Here Is Why (StockStory)
Nov-24-25 10:16AM	Amphastar Pharmaceuticals- Growth has been impressive, Can it continue? (GuruFocus.com)
06:00AM	Amphastar Pharmaceuticals to Present at the 37th Annual Piper Sandler Healthcare Conference (ACCESSWIRE)
Nov-13-25 12:34AM	5 Must-Read Analyst Questions From Amphastar Pharmaceuticals's Q3 Earnings Call (StockStory) -5.25%
Nov-12-25 03:20PM	Why Amphastar Pharmaceuticals (AMPH) Stock Is Trading Up Today (StockStory)
06:00AM	Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (ACCESSWIRE)
Nov-11-25 10:31PM	Generic Pharmaceuticals Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) Simply the Best (StockStory)
Nov-10-25 03:21PM	Why Are Amphastar Pharmaceuticals (AMPH) Shares Soaring Today (StockStory) +8.70%
10:31AM	AMPH Q3 Deep Dive: Pipeline Expansion and Core Product Growth Offset Margin Pressures (StockStory)
Nov-07-25 10:01PM	Amphastar Pharmaceuticals Inc (AMPH) Q3 2025 Earnings Call Highlights: Strong Core Product ... (GuruFocus.com)
01:11PM	Why Amphastar Pharmaceuticals (AMPH) Stock Is Up Today (StockStory)
Nov-06-25 06:30PM	Here's What Key Metrics Tell Us About Amphastar (AMPH) Q3 Earnings (Zacks)
05:55PM	Amphastar Pharmaceuticals (AMPH) Q3 Earnings and Revenues Top Estimates (Zacks)
05:09PM	Amphastar Pharmaceuticals (NASDAQ:AMPH) Delivers Strong Q3 Numbers (StockStory)
04:55PM	Amphastar: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025 (ACCESSWIRE)
Nov-04-25 10:10PM	Amphastar Pharmaceuticals (AMPH) To Report Earnings Tomorrow: Here Is What To Expect (StockStory)
05:30PM	Personalis (PSNL) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Oct-30-25 10:00AM	Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-28-25 10:40AM	Should Investors Buy CorMedix Stock Ahead of Q3 Earnings Report? (Zacks)
Oct-27-25 06:00AM	Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2025 (ACCESSWIRE)
12:01AM	2 Reasons AMPH is Risky and 1 Stock to Buy Instead (StockStory)
Oct-20-25 10:10AM	How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results? (Zacks)
Oct-17-25 09:40AM	Should Value Investors Buy Amphastar Pharmaceuticals (AMPH) Stock? (Zacks)
09:35AM	Down 15.4% in 4 Weeks, Here's Why Amphastar (AMPH) Looks Ripe for a Turnaround (Zacks)
Oct-14-25 10:38AM	CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip? (Zacks)
Oct-07-25 10:32AM	Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In? (Zacks)
Sep-23-25 10:44AM	CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick? (Zacks)
Sep-18-25 10:54AM	Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification? (Zacks)
Sep-15-25 10:27AM	CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock? (Zacks)
Sep-04-25 11:32PM	A Look Back at Generic Pharmaceuticals Stocks' Q2 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Pack (StockStory)
Sep-02-25 10:18AM	Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path? (Zacks)
08:46AM	Is the Options Market Predicting a Spike in Amphastar Pharmaceuticals Stock? (Zacks)
04:06AM	Amphastar Pharmaceuticals, Inc. (AMPH) Secures FDA Approval for Generic Iron Sucrose Injection (Insider Monkey)
Aug-28-25 06:00AM	Amphastar Pharmaceuticals to Present at the 2025 Wells Fargo Healthcare Conference (ACCESSWIRE)
Aug-14-25 01:42AM	05 Insightful Analyst Questions From Amphastar Pharmaceuticals's Q2 Earnings Call (StockStory)
Aug-13-25 07:33AM	Amphastar and Anji make licence agreement for three new peptides (Pharmaceutical Technology)
Aug-12-25 02:20PM	Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know (StockStory) +10.93%
01:38PM	Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum (Benzinga)
06:00AM	Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd. (ACCESSWIRE)
03:25AM	AMPH Q2 Deep Dive: BAQSIMI Momentum, Margin Pressures, and Pipeline Milestones (StockStory)
Aug-11-25 12:31PM	Why Is Amphastar Pharmaceuticals (AMPH) Stock Soaring Today (StockStory) +14.91%
06:00AM	Amphastar Announces FDA Approval for Iron Sucrose Injection, USP (ACCESSWIRE)
Aug-08-25 11:00PM	Amphastar Pharmaceuticals Inc (AMPH) Q2 2025 Earnings Call Highlights: Strong Vaccine Sales and ... (GuruFocus.com) +10.13%
09:40AM	Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now? (Zacks)
04:57AM	Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q2 Sales Targets, But Stock Soars 6% (StockStory)
Aug-07-25 05:30PM	Amphastar (AMPH) Reports Q2 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:17PM	Amphastar: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2025 (ACCESSWIRE)
Aug-05-25 11:19PM	Amphastar Pharmaceuticals (AMPH) Reports Q2: Everything You Need To Know Ahead Of Earnings (StockStory)
05:25PM	BridgeBio Pharma (BBIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Aug-04-25 10:00AM	Will Taysha Gene Therapies, Inc. (TSHA) Report Negative Q2 Earnings? What You Should Know (Zacks)
Jul-31-25 10:00AM	Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-30-25 08:25PM	Bausch Health (BHC) Lags Q2 Earnings Estimates (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PETERS WILLIAM J	CFO, EVP & TREASURER	Sep 21 '26	Sale	25.00	4,139	103,475	168,707	Sep 23 06:02 PM
PETERS WILLIAM J	Officer	Sep 21 '26	Proposed Sale	25.00	4,139	103,475		Sep 21 06:37 PM
Zhou Rong	SENIOR EVP, PRODUCTION CENTER	Sep 16 '26	Option Exercise	13.35	10,000	133,500	179,203	Sep 17 06:19 PM
Zhou Rong	SENIOR EVP, PRODUCTION CENTER	Sep 16 '26	Sale	23.94	10,000	239,404	169,203	Sep 17 06:19 PM
Zhou Rong	SENIOR EVP, PRODUCTION CENTER	Sep 02 '26	Sale	23.63	3,187	75,306	169,203	Sep 03 07:42 PM
Rong Zhou	Vice President	Sep 01 '26	Proposed Sale	22.00	13,187	290,114		Sep 01 04:25 PM
Floyd Petersen	Director	Aug 18 '26	Proposed Sale	21.00	47,101	989,121		Aug 18 05:56 PM
PRINS RICHARD K	Director	Aug 11 '26	Sale	20.30	7,973	161,852	29,625	Aug 12 06:14 PM
PETERS WILLIAM J	CFO, EVP & TREASURER	Aug 07 '26	Option Exercise	19.79	5,053	99,999	181,026	Aug 11 04:57 PM
PETERS WILLIAM J	CFO, EVP & TREASURER	Aug 07 '26	Sale	22.48	8,180	183,886	172,846	Aug 11 04:57 PM
Richard Prins	Director	Aug 11 '26	Proposed Sale	20.31	7,973	161,932		Aug 11 11:53 AM
PETERS WILLIAM J	Officer	Aug 07 '26	Proposed Sale	22.48	8,180	183,886		Aug 07 04:09 PM
Zhou Rong	SENIOR EVP, PRODUCTION CENTER	Dec 17 '25	Option Exercise	11.33	9,787	110,887	147,830	Dec 18 05:23 PM
Zhou Rong	SENIOR EVP, PRODUCTION CENTER	Dec 17 '25	Sale	26.20	9,787	256,379	138,043	Dec 18 05:23 PM
Petersen Floyd F.	Director	Dec 12 '25	Sale	25.92	2,426	62,888	71,368	Dec 15 05:17 PM
Petersen Floyd F.	Director	Dec 11 '25	Sale	25.69	1,737	44,620	73,794	Dec 15 05:17 PM
Floyd Petersen	Director	Dec 11 '25	Proposed Sale	80.00	4,163	333,040		Dec 11 05:17 PM
Floyd Petersen	Director	Dec 10 '25	Proposed Sale	25.00	1,737	43,425		Dec 10 02:40 PM
Rong Zhou	Officer	Nov 28 '25	Proposed Sale	25.00	20,000	500,000		Nov 28 01:23 PM
PRINS RICHARD K	Director	Nov 25 '25	Option Exercise	16.69	4,179	69,748	39,362	Nov 25 07:38 PM
PRINS RICHARD K	Director	Nov 25 '25	Sale	27.10	4,179	113,253	35,183	Nov 25 07:38 PM
Richard Prins	Director	Nov 25 '25	Proposed Sale	25.00	4,179	104,475		Nov 25 05:05 PM
Petersen Floyd F.	Director	Nov 13 '25	Option Exercise	16.69	16,679	278,373	92,210	Nov 17 04:16 PM
Petersen Floyd F.	Director	Nov 13 '25	Sale	26.49	16,679	441,837	75,531	Nov 17 04:16 PM
Floyd Petersen	Director	Nov 13 '25	Proposed Sale	26.49	16,679	441,837		Nov 13 05:06 PM
Petersen Floyd F.	Director	Nov 03 '25	Sale	25.27	500	12,633	75,531	Nov 05 04:20 PM
Petersen Floyd F.	Director	Nov 03 '25	Proposed Sale	25.30	500	12,650		Nov 03 04:24 PM

Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, and commercializing technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredients. It operates through Pharmaceutical Products segment. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Chairman of the BoardDr. Ziping Luo Ph.D.

Co-FounderDr. Yongfeng Zhang Ph.D.

CFOMr. William J. Peters M.B.A.

Executive VP of SalesMr. Jacob Liawatidewi M.B.A.

Senior EVP of Production & EVP of Scientific AffairsMr. Rong Zhou M.S.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Amphastar Pharmaceuticals Inc

Upgrade your Finviz experience